Aventis Named to List of Top 100 Companies for Working Mothers

Aventis Named to List of Top 100 Companies for Working Mothers
Receives Honors Three Years Running 


BRIDGEWATER, N.J., Sept. 21  /PRNewswire-FirstCall/ -- For the third year in a
row, Aventis has been named to Working Mother magazine's list of the 100 Best
Companies for Working Mothers.  Aventis was selected based on its family-
friendly corporate culture, work/life policies and total compensation package.

"We appreciate the ongoing recognition by Working Mother magazine of our
continued efforts to make Aventis a great place to work," said Susan Ketterman,
Vice President of North America Human Resources for Aventis.

"Aventis is now moving on to a new phase, becoming Sanofi-Aventis," Ketterman
continued.  "However, a bedrock principle upon which Aventis was founded is
that the company can only succeed by attracting and retaining the very best
associates. Providing options that support work/life balance for our associates
is a priority."

Aventis was first named to Working Mother magazine's prestigious list in 2002. 
Family friendly benefits offered by Aventis include a competitive compensation
package, flexible work options, a standard of four weeks vacation for every
full-time employee, and numerous training and educational programs.

About Aventis

Aventis is dedicated to treating and preventing disease by discovering and
developing innovative prescription drugs and human vaccines. In 2003, Aventis
generated sales of euro 16.79 billion (US $18.99), invested euro 2.86 billion
(US $3.24) in research and development and employed approximately 69,000 people
in its core business. Aventis corporate headquarters are in Strasbourg, France.
The company's prescription drugs business is conducted in the U.S. by Aventis
Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. For
more information, please visit: http://www.aventis-us.com/.

Statements in this news release containing projections or estimates of
revenues, income, earnings per share, capital expenditures, capital structure,
or other financial items; plans and objectives relating to future operations,
products, or services; future economic performance; or assumptions underlying
or relating to any such statements, are forward-looking statements subject to
risks and uncertainties. Actual results could differ materially depending on
factors such as the timing and effects of regulatory actions, the results of
clinical trials, the company's relative success developing and gaining market
acceptance for new products, the outcome of significant litigation, and the
effectiveness of patent protection. Additional information regarding risks and
uncertainties is set forth in the current Annual Report on Form 20-F of Aventis
on file with the Securities and Exchange Commission and in the current Annual
Report -- "Document de Reference" -- on file with the "Autorite des marches
financiers." 

DATASOURCE: Aventis



CONTACT:  Christine Kirby of Aventis, [phone], or

 



Web site:  http://www.aventis-us.com/ 

Copyright